NIH PAR · NCI · R01
PAR-25-145: Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping…
- NOFO number
- PAR-25-145
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Nov 6, 2024
- Opens
- Jan 5, 2025
- Expires
- Jan 8, 2028
PAR-25-145 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 05, 2025 | July 05, 2025 * | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 05, 2025 | November 05, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 05, 2026 | July 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 05, 2027 | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-145
NIH RePORTER lists 11 projects funded under PAR-25-145 in FY2022–FY2026, with $6.9M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
11
Distinct projects, FY2022–FY2026
New awards
11
Type 1 (new project) award records
NIH funding
$6.9M
Award dollars under PAR-25-145, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 11 | 11 | $6.9M |
Institutions with the most funding
- University of California, San Francisco$1.3M · 2 projects
- Brigham and Women's Hospital$816K · 1 project
- University of Rochester$815K · 1 project
- Rutgers Biomedical and Health Sciences$652K · 1 project
- Washington University$645K · 1 project
- University of Maryland Baltimore$598K · 1 project
- Saint Louis University$584K · 1 project
- Oregon Health & Science University$576K · 1 project
Most recent new awards
- Discovery of a novel target to mitigate cancer-therapy induced neurocognitive impairments (opens NIH RePORTER)
Saint Louis University · 1R01CA310975-01 · NCI · Notice Sep 17, 2026
$584KR01
- Radiation therapy damage to airways and vessels: determining impact on ventilation, perfusion, and radiation-induced lung injury (opens NIH RePORTER)
Oregon Health & Science University · 1R01CA309192-01 · NCI · Notice Sep 8, 2026
$576KR01
- Understanding the contribution of Toll-like receptor 4 activity in mesenchymal stromal cells to cancer treatment induced skeletal muscle decline and fibrosis (opens NIH RePORTER)
Duke University · 1R01CA309759-01A1 · NCI · Notice Aug 31, 2026
$434KR01
- Neural and Developmental Mechanisms of Cisplatin Ototoxicity (opens NIH RePORTER)
Medical University of South Carolina · 1R01CA313899-01A1 · NCI · Notice Aug 31, 2026
$478KR01
- Targeting the Meningeal Lymphatic System in Chemobrain (opens NIH RePORTER)
Rutgers Biomedical and Health Sciences · 1R01CA317843-01 · NCI · Notice Aug 27, 2026
$652KR01
- Precision Imaging of Cardiotoxicity: Metabolic MR Biomarkers for Pathophysiology, Early Detection, and Cardioprotection Effect Monitoring (opens NIH RePORTER)
University of California, San Francisco · 1R01CA316800-01 · NCI · Notice Aug 12, 2026
$636KR01
What its predecessor PAR-21-329 funded
PAR-25-145 reissues PAR-21-329. Its funding history is the best guide to who wins under this program: 24 projects and $44.3M in FY2022–FY2026.
Projects funded
24
Distinct projects, FY2022–FY2026
New awards
24
Type 1 (new project) award records
NIH funding
$44.3M
Award dollars under PAR-21-329, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 12 | 12 | $6.5M |
| FY2024 | 19 | 7 | $9.7M |
| FY2025 | 23 | 5 | $13.3M |
| FY2026 | 23 | 0 | $14.8M |
Institutions with the most funding
- Sloan-Kettering Inst Can Research$4.8M · 3 projects
- University of California-Irvine$3.6M · 2 projects
- Columbia University Health Sciences$3.2M · 1 project
- Rutgers Biomedical and Health Sciences$3.0M · 1 project
- Vanderbilt University Medical Center$2.9M · 1 project
- Ohio State University$2.6M · 1 project
- University of Colorado Denver$2.5M · 1 project
- University of Pittsburgh at Pittsburgh$2.5M · 1 project
Most recent new awards
- Development of a Personalized Voxel-wise Prediction of Brain Metastases using Multi-Parametric MR Imaging to Reduce Treatment Toxicity (opens NIH RePORTER)
University of California, San Francisco · 1R01CA292043-01A1 · NCI · Notice Aug 20, 2025
$730KR01
- Mechanistic Insight to Predict and Prevent Nilotinib-Induced Artery Disease (opens NIH RePORTER)
Northwestern University · 1R01CA292427-01A1 · NCI · Notice Jul 23, 2025
$645KR01
- Protecting the kidney from cisplatin induced injury and progression to chronic kidney disease (opens NIH RePORTER)
University of Louisville · 1R01CA305985-01 · NCI · Notice Jun 12, 2025
$649KR01
- Non-invasive, quantitative microscopic biomarkers for chemotherapy-induced peripheral neuropathy (opens NIH RePORTER)
University of Arizona · 1R01CA301271-01 · NCI · Notice Feb 21, 2025
$391KR01
- Mechanisms of Radiation-Induced Neurocognitive Decline (MIND): Longitudinal Study of Imaging Biomarkers and Risk and Resilience Factors Underlying Cognitive Phenotypes in Patients with Glioma (opens NIH RePORTER)
University of California, San Diego · 1R01CA289833-01A1 · NCI · Notice Dec 5, 2024
$667KR01
- Comprehensive Molecular and Clinical Characterization of Acute and Chronic Neurotoxicity Following CAR-T Cell Therapy (opens NIH RePORTER)
Sloan-Kettering Inst Can Research · 1R01CA293922-01 · NCI · Notice Sep 2, 2024
$610KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-145. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is 5 years.    NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-329.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.